Gatifloxacin

Drug Profile

Gatifloxacin

Alternative Names: AM 1155; BMS 206584; Bonoq; Bonoq Uro; CG 5501; Gatiflo; Gesetz; Tequin; Zymar; Zymaxid

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Kyorin Pharmaceutical
  • Developer Allergan; Kyorin Pharmaceutical; Senju Pharmaceutical
  • Class Antibacterials; Fluoroquinolones; Small molecules
  • Mechanism of Action Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Infectious conjunctivitis
  • Market Withdrawal Acute exacerbations of chronic bronchitis; Bacterial infections; Chlamydial infections; Gonorrhoea; Pneumonia; Respiratory tract infections; Sinusitis; Skin and soft tissue infections; Urinary tract infections
  • Discontinued Anthrax; Otitis media

Most Recent Events

  • 06 Feb 2017 Gatifloxacin is still in under Preregistration for Infectious conjunctivitis in China (Ophthalmic)
  • 19 Jun 2014 Dainippon Sumitomo Pharma is now called Sumitomo Dainippon Pharma
  • 03 Oct 2013 First generic equivalent available in USA for Infectious conjunctivitis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top